Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis

被引：0
|
作者：
Papp, K. [1 ]
Griffiths, C. E. M. [2 ]
Gordon, K. [3 ]
Lebwohl, M. [4 ]
Szapary, P. O. [5 ]
Wasfi, Y. [5 ]
Chan, D. [5 ]
Shen, Y. K. [5 ]
Ho, V. [6 ]
Ghislain, P. D. [7 ]
Strober, B. [8 ]
Reich, K. [9 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Univ Manchester, Manchester Acad Hlth Sci Ctr, Dermatol Ctr, Manchester, Lancs, England
[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[4] Mt Sinai Sch Med, New York, NY USA
[5] Janssen Res & Dev LLC, Spring House, PA USA
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium
[8] Univ Connecticut, Sch Med, Dept Dermatol, Farmington, CT USA
[9] Dermatologikum Hamburg, Hamburg, Germany
来源：
SWISS MEDICAL WEEKLY | 2014年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P 14
引用
下载
收藏
页码：5S / 5S
页数：1
相关论文
共 50 条
  • [1] Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis
    Papp, Kim
    Griffiths, Christopher E. M.
    Gordon, Kenneth B.
    Lebwohl, Mark
    Szapary, Philippe O.
    Wasfi, Yasmine
    Chan, Daphne
    Shen, Yaung-Kaung
    Ho, Vincent
    Ghislain, Pierre-Dominique
    Strober, Bruce
    Reich, Kristian
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S139 - S140
  • [2] Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis
    Papp, Kim
    Reich, Kristian
    Lebwohl, Mark
    Wasfi, Yasmine
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB174 - AB174
  • [3] LONG-TERM SAFETY OF USTEKINUMAB: 5 YEARS OF FOLLOW-UP FROM THE PSORIASIS CLINICAL DEVELOPMENT PROGRAM INCLUDING PATIENTS WITH PSORIATIC ARTHRITIS
    Papp, K.
    Griffiths, C.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Shen, Y. K.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 680 - 680
  • [4] Long-term safety of ustekinumab: Five years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis
    Papp, K.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Shen, Y. K.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 30 - 30
  • [5] An Update on the Long-Term Safety Experience of Ustekinumab: Results From the Psoriasis Clinical Development Program With up to Four Years of Follow-Up
    Reich, Kristian
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Szapary, Philippe O.
    Yeilding, Newman
    Wasfi, Yasmine
    Ott, Elyssa
    Hsu, Ming-Chun
    Lebwohl, Mark
    Gordon, Kenneth B.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (03) : 300 - 312
  • [6] Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-up from the Psoriatic Arthritis Clinical Development Program
    Kavanaugh, Arthur
    McInnes, Iain B.
    Ritchlin, Christopher T.
    Rahman, Proton
    Puig Sanz, Lluis
    Gottlieb, Alice B.
    Song, Michael
    Randazzo, Bruce
    Li, Shu
    You, Yin
    Mendelsohn, Alan M.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S686 - S687
  • [7] INTEGRATED SAFETY OF USTEKINUMAB IN PSORIATIC ARTHRITIS: 2 YEAR FOLLOW-UP FROM THE PSORIATIC ARTHRITIS CLINICAL DEVELOPMENT PROGRAM
    Kavanaugh, A.
    McInnes, I.
    Ritchlin, C.
    Rahman, P.
    Puig, L.
    Gottlieb, A.
    Song, M.
    Randazzo, B.
    Li, S.
    You, Y.
    Mendelsohn, A. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 350 - 350
  • [8] Long-term safety of ustekinumab in patients with moderate to severe psoriasis through up to 5 years of continuous follow-up
    Papp, Kim
    Reich, Kristian
    Lebwohl, Mark
    Szapary, Philippe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB205 - AB205
  • [9] Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
    Papp, K. A.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. -C.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (04) : 844 - 854
  • [10] Ustekinumab safety update: cumulative experience from longer term follow-up of patients treated in the ustekinumab psoriasis clinical development program
    Gordon, K.
    Leonardi, C.
    Griffiths, C. E.
    Szapary, P. O.
    Yeilding, N.
    Hsu, M. C.
    Wasel, N.
    Prinz, J.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 21 - 22
12345